Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C

Thrombosis and Haemostasis

Volumn 95, Issue 2, 2006, Pages 260-266

  Sieghart, Wolfgang ^a   Homoncik, Monika ^a   Jilma, Bernd ^a   Formann, Elisabeth ^a   Ferenci, Peter ^a   Gangl, Alfred ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clinical epidemiological studies; Platelet activation markers; von Willebrand factor

Indexed keywords

ANTIVIRUS AGENT; BETA THROMBOGLOBULIN; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PARACETAMOL; PEGINTERFERON ALPHA2A; RIBAVIRIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION;

ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYETHYLENE GLYCOLS; RIBAVIRIN; VON WILLEBRAND FACTOR;

EID: 33645550656     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-12-0781     Document Type: Article

References (32)

1. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (5 Suppl 1): S237-S244.
2. Shrestha R, McKinley C, Bilir BM, et al. Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1995; 90: 1146-7.
3. Pockros PJ, Duchini A, McMillan R, et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002; 97: 2040-5.
4. Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon α-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 1424-9.
5. Panzer S, Seel E. Is there an increased frequency of autoimmune thrombocytopenia in hepatitis C infection? A review. Wien Med Wochenschr 2003; 153: 417-20.
6. Verfaillie CM, Bhatia R, Browne P, et al. Interferon-α restores β1-integrin-dependent, collagen-mediated platelet aggregation in a patient with chronic myelogenous leukemia. J Lab Clin Med 1998; 131: 163-9.
7. Catani L, Gugliotta L, Cascione ML, et al. Platelet function and interferon α-2a treatment in essential thrombocythaemia. Eur J Haematol 1991; 46: 158-62.
8. Gutman H, Schachter J, Stopel E, et al. Impaired platelet aggregation in melanoma patients treated with interferon-α-2b adjuvant therapy. Cancer 2002; 94: 780-5.
9. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
10. Seymour RA, Williams FM, Oxley A, et al. A comparative study of the effects of aspirin and paracetamol (acetaminophen) on platelet aggregation and bleeding time. Eur J Clin Pharmacol 1984; 26: 567-71.
11. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-9.
12. Shattil SJ, Hoxie JA, Cunningham M, et al. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-14.
13. Homoncik M, Jilma B, Donham DC, et al. Activation of calcium-dependent calmodulin by calcium (II)3(3,5-diisopropylsalicylate)6(H2O)6 decreases thrombin receptor activating peptide-induced P-selectin expression. Blood Coagul Fibrinolysis 2003; 14: 131-8.
14. Pineda AA, Zylstra VW, Clare DE, et al. Viability and functional integrity of washed platelets. Transfusion 1989; 29: 524-7.
15. Perry CM, Jarvis B. Peginterferon-α-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001; 61: 2263-88.
16. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152-63.
17. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111: 733-44.
18. Homoncik M, Blann AD, Hollenstein U, et al. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100 Br J Haematol 2000; 111: 1250-2.
19. Reiter RA, Mayr F, Blazicek H, et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102: 4594-9.
20. Nusinow SR, Federici AB, Zimmerman TS, et al. Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum 1984; 27: 1405-10.
21. Stevens TR, James JP Simmonds NJ, et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33: 502-6.
22. Michelson AD, Ellis PA, Barnard MR, et al. Down-regulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. Blood 1991; 77: 770-9.
23. Shattil SJ. Signaling through platelet integrin αIIbβ3: inside-out, outside-in, and sideways. Thromb Haemost 1999; 82: 318-25.
24. Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6: 342-8.
25. Heyns AD, Lotter MG, Badenhorst PN, et al. Kinetics, distribution and sites of destruction of 111 indium-labelled human platelets. Br J Haematol 1980; 44: 269-80.
26. Stohlawetz P, Horvath M, Pernerstorfer T, et al. Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans. Transfusion 1999; 39: 506-14.
27. Poujol C, Nurden A, Paponneau A, et al. Ultra structural analysis of the distribution of von Willebrand factor and fibrinogen in platelet aggregates formed in the PFA-100. Platelets 1998; 9: 381-9.
28. Moeller A, Weippert-Kretschmer M, Prinz H, et al. Influence of ABO blood groups on primary hemostasis. Transfusion 2001; 41: 56-60.
29. Chakroun T, Gerotziafas G, Robert F, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 80-5.
30. Tomokiyo K, Kamikubo Y, Hanada T, et al. Von Willebrand factor accelerates platelet adhesion and thrombus formation on a collagen surface in platelet-reduced blood under flow conditions. Blood 2005; 105: 1078-84.
31. Roche. Investigator's brochure for PegInterferon alpha 2a. 2003.
32. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.